Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc., commonly known as AskBio, is a pioneering gene therapy company headquartered in the United States. Founded in 2001, AskBio has established itself as a leader in the biotechnology industry, focusing on the development of innovative gene therapies for rare and serious diseases. With major operational regions across North America and Europe, the company is dedicated to advancing its proprietary adeno-associated virus (AAV) platform, which enables targeted delivery of genetic material to treat various conditions.
Asklepios BioPharmaceutical's core offerings include cutting-edge gene therapies that leverage its unique AAV technology, setting it apart in the competitive landscape. The company has achieved significant milestones, including strategic partnerships and advancements in clinical trials, solidifying its position as a key player in the gene therapy market. With a commitment to transforming patient care, AskBio continues to push the boundaries of science and medicine.
+48 vs industry average
Asklepios BioPharmaceutical, Inc.’s score of 86 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Asklepios BioPharmaceutical, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Asklepios BioPharmaceutical, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Asklepios BioPharmaceutical, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Asklepios BioPharmaceutical, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Bayer Aktiengesellschaft
Carbon Disclosure Project
Inherited from Bayer AktiengesellschaftThe Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Bayer AktiengesellschaftRE 100
Climate Action 100
Inherited from Bayer AktiengesellschaftEmissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project